184 related articles for article (PubMed ID: 36915248)
1. Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single- Center Study.
Liu X; Gong C; Zhang J; Feng W; Guo Y; Sang Y; Wang C; Chen Y; Wang J; Yu L; Zhang X; Luo Z
Cancer Res Treat; 2023 Jul; 55(3):1001-1010. PubMed ID: 36915248
[TBL] [Abstract][Full Text] [Related]
2. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
[TBL] [Abstract][Full Text] [Related]
4. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib in ALK
Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
[TBL] [Abstract][Full Text] [Related]
6. ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.
Xu X; Li H; Peng K; Yu Y; Chen L; Fang Y; Sun Y; Hou Y; Liu T
Oncol Lett; 2019 Feb; 17(2):2370-2376. PubMed ID: 30675302
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological features of inflammatory myofibroblastic tumor].
Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
[No Abstract] [Full Text] [Related]
8. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract][Full Text] [Related]
9. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.
Ogata M; Hatachi Y; Ogata T; Satake H; Imai Y; Yasui H
Intern Med; 2019 Apr; 58(7):1029-1032. PubMed ID: 30449794
[TBL] [Abstract][Full Text] [Related]
11. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.
Baldi GG; Brahmi M; Lo Vullo S; Cojocaru E; Mir O; Casanova M; Vincenzi B; De Pas TM; Grignani G; Pantaleo MA; Blay JY; Jones RL; Le Cesne A; Frezza AM; Gronchi A; Collini P; Dei Tos AP; Morosi C; Mariani L; Casali PG; Stacchiotti S
Oncologist; 2020 Nov; 25(11):e1777-e1784. PubMed ID: 32584482
[TBL] [Abstract][Full Text] [Related]
12. Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review.
Singh P; Nambirajan A; Gaur MK; Raj R; Kumar S; Malik PS; Jain D
J Pathol Transl Med; 2022 Jul; 56(4):231-237. PubMed ID: 35843628
[TBL] [Abstract][Full Text] [Related]
13. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
14. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
15. Epithelioid Inflammatory Myofibroblastic Sarcoma With Poor Response to Crizotinib: A Case Report.
Aminimoghaddam S; Pourali R
Clin Med Insights Case Rep; 2023; 16():11795476231163954. PubMed ID: 37841512
[TBL] [Abstract][Full Text] [Related]
16. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
[TBL] [Abstract][Full Text] [Related]
17. Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib.
Li M; Xing R; Huang J; Shi C; Wei C; Wang H
Front Oncol; 2023; 13():1084456. PubMed ID: 37035183
[TBL] [Abstract][Full Text] [Related]
18. Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature.
Yu L; Liu J; Lao IW; Luo Z; Wang J
Diagn Pathol; 2016 Jul; 11(1):67. PubMed ID: 27460384
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.
Coffin CM; Hornick JL; Fletcher CD
Am J Surg Pathol; 2007 Apr; 31(4):509-20. PubMed ID: 17414097
[TBL] [Abstract][Full Text] [Related]
20. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
